Ocular distribution of intravenously administered micafungin in rabbits

Journal of Infection and Chemotherapy

Volumn 14, Issue 3, 2008, Pages 204-207

  Suzuki, Takashi ^a,b   Uno, Toshihiko ^a   Chen, Guangming ^a   Ohashi, Yuichi ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE   (United States)

Author keywords

Eye; Fluconazole; Fungi; Micafungin; Pharmacokinetics; Rabbit

Indexed keywords

FLUCONAZOLE; MICAFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS; CANDIDA; CHOROID; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; ENDOPHTHALMITIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RABBIT; RETINA; TIME TO MAXIMUM PLASMA CONCENTRATION; VITREOUS BODY;

EID: 45749146617     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-008-0612-5     Document Type: Article

References (22)

1. Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother 1987;31:6-10.
2. Isobe Y, Hatano H. Study of suppressive effect of intravenous fluconazole on endogenous Candida endophthalmitis in rabbits. Jpn J Ophthalmol 1992;36:23-27.
3. Louie A, Liu W, Miller DA, Sucke AC, Liu Q-F, Drusano GL, et al. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Antimicrob Agents Chemother 1999;43:2831-2840.
4. Giusiano G, Mangiaterra M, Garcia Saito V, Rojas F, Gomez V, Diaz MC. Fluconazole and itraconazole resistance of yeasts isolated from the bloodstreamand catheters of hospitalized pediatric patients. Chemotherapy 2006;52:254-259.
5. Nakamura T, Takahashi H. Epidemiological study of Candida infections in blood: susceptibilities of Candida spp. to antifungal agents, and clinical features associated with the candidemia. J Infect Chemother 2006;12:132-138.
6. Osthoff M, Hilge R, Schulze-Dobold C, Bogner JR. Endogenous endophthalmitis with azole-resistant Candida albicans - case report and review of the literature. Infection 2006;34:285-288.
7. Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, Vidal AM. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis 2005;40:e46-e48.
8. Ikeda F, Otomo K, Nakai T, Morishita Y, Maki K, Tawara S, et al. In vitro activity of a new lipopeptide antifungal agent, micafungin, against a variety of clinically important fungi. Jpn J Chemother 2002;50(Suppl 1):8-19.
9. Watabe E, Nakai T, Matsumoto F, Ikeda F, Hatano K. Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorecent staining for cell viability. Antimicrob Agents Chemother 2003;47:1995-1998.
10. Groll AH, Mickiene D, Petraitis V, Petraitiene R, Ibrahim KH, Piscitelli SC, et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001;45:3322-3327.
11. Niwa T, Yokota Y, Tokunaga A, Yamato Y, Kagayama A, Fujiwara T, et al. Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats. Biol Pharm Bull 2004;27:1154-1156.
12. Yamato Y, Kaneko H, Yamasaki S, Fujiwara T, Katashima M, Ishibashi K, et al. Simultaneous determination of antifungal drug, micafungin, and its two active metabolites in human plasma using high-performance liquid chromatography with fluorescence detection. Jpn J Chemother 2002;50(Suppl 1):68-73.
13. Koks CH, Rosing H, Meenhorst PL, Bult A, Beijnen JH. High-performance liquid chromatographic determination of the antifungal drug fluconazole in plasma and saliva of human immunodeficiency virus-infected patients. J Chromatogr B Biomed Appl 1995;663:345-351.
14. Balani SK, Nagaraja NV, Qian MG, Costa AO, Daniels JS, Yang H, et al. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drug Metab Dispos 2006;34:384-388.
15. Niwa T, Shiraga T, Takagi A. Drug-drug interaction of antifungal drugs, Yakugaku Zasshi 2005;125:795-805.
16. Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin J, et al. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol 2005;57:759-764.
17. Keirns J, Sawamoto T, Holum M, Buell D, Wisemandle W, Alak A. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob Agents Chemother 2007;51:787-790.
18. Samiy N, D'Amico DJ. Endogenous fungal endophthalmitis. Int Ophthalmol Clin 1996;36:147-162.
19. Rao NA, Hidayat AA. Endogenous mycotic endophthalmitis: variations in clinical and histopathologic changes in candidiasis compared with aspergillosis. Am J Ophthalmol 2001;132:244-251.
20. Azuma J, Nakahara K, Kagayama A, Okuma T, Kawamura A, Mukai T. Pharmacokintic study of micafungin. Jpn J Chemother 2002;50(Suppl 1):155-184.
21. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996;82:511-516.
22. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 1997;51:415-419.